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Abstract
The field of therapeutic focused ultrasound, which first emerged in the 1940s, has seen significant growth,
particularly over the past decade. The eventual widespread clinical adoption of this non-invasive therapeutic
modality require continued progress, in a multitude of activities including technical, pre-clinical, and clinical
research, regulatory approval and reimbursement, manufacturer growth, and other commercial and public sector
investments into the field, all within a multi-stakeholder environment. We present here a snapshot of the field of
focused ultrasound and describe how it has progressed over the past several decades. It is assessed using metrics
which include quantity and breadth of academic work (presentations, publications), funding trends, manufacturer
presence in the field, number of treated patients, number of indications reaching first-in-human status, and quantity
and breadth of clinical indications.
Content
Introduction
The first publication to demonstrate focused ultrasound's
potential therapeutic use appeared in 1942 [1]. Over the
following decade, focused ultrasound was investigated as a
potential treatment for neurofunctional disorders, specif-
ically Parkinson's disease [2,3]. At this initial stage, the
transmission of acoustic energy into the brain was an in-
vasive procedure because of the reflection, absorption,
and diffraction produced by the skull. Real-time image
guidance was not available at the time. An offline X-ray
was therefore used to guide the beams from the single-
element therapeutic ultrasound transducers which were
mounted on a stereotactic frame.
The Food and Drug Administration (FDA) first ap-
proved a focused ultrasound (FUS) device in 1988 [4,5].
This device provided non-invasive treatment of glau-
coma under ultrasound and optical imaging guidance
[6-8].
In the 1950s, Vallancien et al. reported clinical results
with a new system that employed ultrasound imaging for
guidance and a thermocouple for thermal measurements.
This system was used to treat patients with bladder cancer
[9] and prostatic, liver, and renal tumors [10]. This led in
2000 to the first Conformité Européenne (CE) approval
for this indication.
Magnetic resonance imaging (MRI)-guided focused
ultrasound devices were introduced in the early 1990s
[11-14], with the first device obtaining CE approval in
2003 and FDA approval in 2004, for the treatment of
symptomatic uterine fibroids.
The development of multielement transducers [15,16]
allowed electronic beam steering around the geometrical
focus [17,18] and the production of multiple simultan-
eous foci [19]. Electronic beam steering can be used ei-
ther to treat large areas without moving the therapeutic
probe [20] or to perform motion compensation [21].
The phase of the signal at each element can also be ad-
justed to provide focusing through aberrating structures
such as the skull [22-27] or the ribs [28-32].
To date, a significant amount of work has been per-
formed using various ultrasound (US)-guided and MRI-
guided systems for the treatment of symptomatic uterine
fibroids [33,34]; brain tumors [35-37]; painful bone me-
tastases [38,39]; prostatic [40-42], pancreatic [43], and
breast [44] cancer; and abdominal tumors [45-47].* Correspondence: ahananel@fusfoundation.org
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To date, more than 80,000 patients have been treated glo-
bally using a variety of ultrasound-guided and MRI-guided
therapeutic high-intensity focused ultrasound devices.
Purpose
In order to evaluate the growth of the field of focused
ultrasound, and to shine a spotlight on its current level
of development and clinical adoption, two primary areas
have been assessed, namely historical progress in finan-
cial support and general awareness of focused ultra-
sound, and the health impacts of the field.
The financial support and general awareness of
focused ultrasound can be assessed by tracking the
amount of research funding provided to focused ultra-
sound projects, the number of publications in peer-
reviewed journals, and general awareness metrics such
as visits to specific focused ultrasound websites, includ-
ing its Wikipedia page.
The impact of focused ultrasound on the health of the
global community can be gleaned through examination of
the number of clinical indications reaching first-in-human
stage and of how many patients have been treated.
Methods
For this evaluation, several metrics and data sources were
used including the annual number of publications (Medline)
and citations (Thompson Reuters Web of Science); the num-
ber of abstracts presented in meetings dedicated to focused
ultrasound (the annual meeting of the International Society
of Therapeutic Ultrasound (ISTU—founded in 2001), the
biennial meeting organized by the Focused Ultrasound
Foundation (FUSF—founded in 2006), and the European
Focused Ultrasound Working Group (EFUS—founded
in 2011)); the clinical indications that have reached the
level of human feasibility trials (obtained from literature
review and communications with relevant researchers);
the number of annual treatments administered (from
manufacturers' reports); manufacturer growth within
the field; and the amount of National Institutes of
Health (NIH) funding allocated to focused ultrasound
research. In addition, the number of hits on the FUS
Foundation website and FUS Wikipedia page were used
as indicators for general awareness of and interest in the
field. This data was used to evaluate the historical pro-
gress and current status of FUS as a treatment modality
for a variety of clinical indications.
The annual number of publications was obtained using
the Medline trends online tool, with the search term
‘focused ultrasound’ which is inclusive for most other
terms used in this field. The Thomson Reuters Web of
Science was used to assess the number of citations per
year, with the same search criterion.
Organizers of focused ultrasound-specific scientific
meetings were contacted in order to assess the number
of abstracts presented at these meetings. Where these
organizers could not be reached, the number of publi-
cations listed in the Proceedings for these conferences
was used.
Manufacturer count and type were obtained by request-
ing information from industry executives, online research,
and information collected through focused ultrasound
symposia registration and sponsorship data. Only manu-
facturers developing an image-guided, non-invasive device
using focused ultrasound for therapy or pre-clinical re-
search, including systems solely for animal research, were
included in these metrics.
The number of patients treated was acquired for each
clinical indication by contacting the relevant device
manufacturers. To identify the time point at which each
clinical indication reached a feasibility clinical trial, the
authors surveyed researchers in the relevant clinical
field, reviewed articles, and conducted specific literature
searches.
NIH funding allocation to focused ultrasound research
was obtained using the NIH RePorter database. The
terms ‘high intensity focused ultrasound,’ ‘focused ultra-
sound therapy,’ ‘ablation,’ ‘drug delivery,’ and ‘HIFU’ were
searched for separately, but the data was aggregated and
duplicates were eliminated. Search results were further
refined based on the relevance of the listed projects.
Data were analyzed and presented by year, total HIFU
annual funding, and funding as a percent of the total
NIH budget. Total annual NIH research spending was
extracted from NIH annual reports. In this work we
present only NIH funding and not funding from sources
in Europe and Asia because these data were not publicly
available in a single location. We assume the NIH fund-
ing could be considered as a surrogate for government
funding worldwide.
The visits to the FUS Foundation website were ana-
lyzed using Listrack and Google analytics. The number
of Wikipedia page views was collected using stats.grok.se
with the key word ‘high-intensity focused ultrasound.’
These general awareness metrics data were analyzed and
are presented by month or quarter, with significant
events highlighted on the timeline.
The data collected and the search terms apply to
therapeutic focused ultrasound, with the majority on it
being for high-intensity focused ultrasound, and thus
distinct from non-focused therapeutic ultrasound that is
used for physiotherapy or other indications.
Results
As shown in Figures 1 and 2, the absolute number of
publications and citations has been increasing since the
beginning of the 1990s as has the ratio of publications
on focused ultrasound to the overall number of publica-
tions in Medline.
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Figure 3 indicates an increase in the number of ab-
stracts presented in FUS centric meetings. A similar
trend of growth is seen in the number of manufacturers
who are developing and selling devices for both clinical
and animal research using various guidance methods as
is shown in Figure 4 and Table 1.
As shown in Figure 5, more than 80,000 patients have
been treated using FUS for multiple clinical indications.
Many more indications are actively being researched and
tested as shown in Figure 6, which demonstrates graph-
ically the date of the first-in-human focused ultrasound
treatment for each indication. Traffic to the FUS
Figure 1 Focused ultrasound publications: annual number and percentage of overall of publications in Medline.
Figure 2 Annual number of citations of focused ultrasound
publications.
Figure 3 Number of abstracts presented at various focused
ultrasound centric meetings: ISTU, EFUS, and FUS
Foundation meetings.
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Foundation website and to the Wikipedia article on fo-
cused ultrasound has been increasing, as can be seen
in Figures 7 and 8, indicating growth in the awareness
of ultrasound. On these two figures, we have also marked
the date of the most recent FUS Foundation symposium
and recent news coverage in ABC, which created a local
peak in the graphs. Additionally, Figure 9 shows that in
the USA, policymaker awareness has also increased, as
FUS has been receiving increased funding and has been
growing in funding relative to total NIH finding.
Discussion
The data presented shows evidence of progress in the
field of focused ultrasound. This is demonstrated by the
number of clinical indications explored, which has in-
creased from 1 to 21 since 1950, or by the increase in
the amount of research as indicated by the steady in-
crease in the number of publications. In addition, the
number of abstracts at focused ultrasound events and
symposia is also on the rise, indicating a higher level of
activity (a similar trend may exist in non-focused
ultrasound-specific symposia but was more challenging
to measure). Publications and citations for focused ultra-
sound have also been increasing yearly and by a greater
percentage than the total number of medical publica-
tions, indicating that focused ultrasound research is
growing faster than medical research overall. A similar
trend of growth could be seen also in the increase in
funding allocated to focused ultrasound and by web traf-
fic in sites dedicated to this topic.
Figure 4 Number of FUS device manufacturers by year of
establishment or entrance into the field of FUS.
Table 1 Focused ultrasound device manufacturers
Company Founded Guidance
and usage
EDAP TMS 1979 US
SonaCare Medical (previously US-HIFU,
International HIFU and Focus Surgery)
1997 US
Chongqing HAIFU 1999 Both
China Medical 1999 US
Insightec 1999 MR
Image Guided Therapy 2001 MR—animals
Shanghai A&S 2001 Both
Mirabilis 2004 US
Theraclion 2004 US
Medsonic 2005 MR
Philips Healthcare 2005 MR
Supersonic Imagine 2005 Both
Profound 2008 MR
EyeTechCare 2008 Visual
Alpinion 2008 US
International Cardio Corporation 2009 US
Kona Medical 2009 US
Histosonic 2009 US
FUS instruments 2009 MR—animals
Acublate 2010 Both
Criteria include guidance method (US, MR, other) and usage (if used only for
pre-clinical studies, this is marked as ‘animal’).
Figure 5 Number of patients treated by focused ultrasound for
various clinical indications.
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This data, however, continues to pose important ques-
tions about metrics and data collection. How can the
community measure progress in a field that is develop-
ing globally across many different clinical indications?
Should progress be measured using translation and ap-
plication or technological capability metrics? How
can public awareness be measured and correlated with
adoption?
Collection of relevant data remains a challenge for the
focused ultrasound community. Most funding data is pub-
licly available only for programs in the USA. This means
that some global impacts cannot, as yet, be measured or
compared. Additionally, research site, manufacturer, and
clinical site information is collected only for the organiza-
tions that actively participate in the focused ultrasound
community and regularly submit their information on a
voluntary basis. This means that it is harder to collect data
Figure 6 Number of indications reaching first-in-human over time.
Figure 7 Number of visits per quarter to the FUS Foundation
website. Figure 8 Number of FUS-specific Wikipedia searches.
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from some regions than others, skewing the geographic
representations of the focused ultrasound field. The Fo-
cused Ultrasound Foundation would like to invite the
community to engage with its business development team
to enable better data collection and increased global
awareness.
Conclusion
The field of therapeutic focused ultrasound has been
steadily growing since its inception in the 1940s. The re-
sults presented here, obtained using quantitative metrics
and publically accessible data sources, offer a snapshot
of the progress in the development and clinical adoption
of this technology. Data indicates that there is wide-
spread progress in scientific and clinical research which
may lead to increased adoption of the technologies for
the benefit of patients worldwide.
This data, however, continues to pose important ques-
tions, particularly for the Focused Ultrasound Foundation.
How can future growth potential be identified and our
resources mobilized to maximize progress in this area?
How can we overcome the barriers along the pathway
from idea conception to successful patient treatment,
to catalyze the process and bring this non-invasive
therapy to patients faster?
The Focused Ultrasound Foundation may be the most
appropriate organization to continue to track the field's
progress. If so, it needs input and guidance from the fo-
cused ultrasound community to strengthen these efforts.
Suggestions for further metrics relevant to the develop-
ment of the field and the sharing of information in the
areas currently being monitored would be welcomed.
The FUS Foundation aims to provide the most accur-
ate information. If you have more current information,
please send it to progress@fusfoundation.org.
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